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Summary 
M eniscus tears have an important socio-economic impact on our society. Each year more than 400,000 surgical interventions are performed on meniscal tears in Europe. In the United States, over 1 million interventions are performed. The majority of meniscal tears 
are situated in the inner avascular zone. In this zone no spontaneous healing is possible. 
The current therapeutic strategy for this type of meniscus tears is partial or subtotal 
meniscectomy according to the dimensions of the tear. Because removal of meniscus tissue 
will finally induce osteoarthrosis of the knee, new therapeutic strategies to substitute or 
replace the damaged meniscus need to be developed. Current research efforts focus on 
tissue engineering. Since the long-term biochemical and biomechanical characteristics of a 
meniscus scaffold are ultimately determined by the cellular phenotype, a combination of a 
well-characterized cell population with a scaffold, appears to be a logical option. Several 
candidate cell-types are of interest for meniscus tissue engineering. Of these, progenitor 
cells have the advantage to be easily expandable without the loss of their differentiation 
potential. The authors present and discuss their current hypothesis for cell-based meniscus 
tissue engineering in combination with a scaffold. 
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1. General introduction 
The meniscus plays an important role in the complex biomechanics of the knee joint. It has a 
function in load bearing, load transmission, shock absorption, joint stability, joint lubrication 
and joint congruity. Loss of this important anatomical structure results in higher peak stresses 
on the cartilage and eventually leads to cartilage degeneration and osteoarthritis, as observed 
by Fairbank, over fifty years ago [1]. 
It is also known that the human meniscus has a poor healing potential, partly due to 
the absence of vasculature. Blood vessels are present only in the outer 10-30% of the meniscal 
body [2]. Lesions located in this area can be surgically sutured with a high success ratio [3]. 
The more frequent lesions, situated in the avascular part, however, show no or only limited 
tendency to heal and should hence be resected [4]. A partial, instead of total meniscectomy is 
proposed, knowing that cartilage degeneration is proportional to the amount of meniscus that 
was removed [5]. Still, partial meniscectomy results in approximately 4% articular cartilage 
volume loss per year [6]. 
Each year more than 400,000 surgical interventions are performed concerning 
meniscal tears in Europe. In the United States, over 1 million interventions are performed. In 
the majority of these interventions, a partial or total meniscectomy is performed. This 
therapeutic intervention causes initially good clinical results but will finally lead to 
osteoarthritis of the knee [1,2].  
Multiple different techniques have been investigated to heal central meniscal lesions. 
These attempts however, remain most frequently unsuccessful [3]. For larger meniscal 
defects, meniscal transplantation is the golden standard. Deep-frozen, cryopreserved or viable 
allografts can be used for this procedure [4,5,6,7,8]. Satisfactory clinical results have been 
obtained on short, middle and long term. These results are independent of the used 
preservation technique. However, recent histological analyses of biopsies taken after 
transplantation of human deep-frozen allografts have shown limited and superficial 
repopulation of the graft by host cells. The core of the graft generally remains acellular. The 
repopulation by acceptor cells from the synovial lining of a deep frozen human meniscus 
graft, seems to be more slowly and incompletely than suggested by animal data.  
Allogenic meniscus transplantation is confronted with potential problems such as 
shape incongruency, disease transmission and a limited availability of donor menisci [9]. In 
2001 we established a meniscus tissue engineering program at our laboratory. Multiple 
different therapeutic strategies to heal or replace a meniscal defect are being investigated. 
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Since ultimately the mechanical and biomechanical characteristics of the graft are determined 
by the cellular phenotype and the number of (host) cells residing within the graft, several cell 
types from different origins are currently under investigation, including bone marrow derived 
mesenchymal stem cells (BMSC), local progenitor cells or differentiated meniscus and 
cartilage cells. In this paper, we will elaborate the use of progenitor cells for meniscus tissue 
engineering applications. 
 
2. Organisation of normal meniscal tissue  
Normal human menisci have been found to be composed of extracellular matrix (ECM), water 
(72%) and cells. The ECM consists of collagen and glycosaminoglycans. 90 % of the collagen 
is collagen type I. The other collagen types are type II, type III, type V and type VI. Due to 
the large amount of collagen type I, the meniscus has properties of fibrous and cartilaginous 
tissue. Type II collagen is expressed in significant amounts in the inner region of the meniscus 
but is absent in the outer vascular region. Aggrecan is a major proteoglycan. Minor 
glycosaminoglycans are decorin, biglycan and fibromodulin [10,11]. These collagen fibers 
and proteoglycans are organized in a complex architecture which provides the tissue-specific 
biomechanical characteristics. This structure is distinctly different from articular cartilage. 
 
3. Histology of the normal human meniscus 
The meniscus is defined as a fibrocartilage, because of the round or oval shape of most of the 
cells and the partially fibrous appearance of the ECM. Ghadially et al. classified cells in the 
meniscus as chondrocytes, fibroblasts or cells of intermediate morphology, based on their 
shape and the presence or absence of a territorial matrix [12]. Type I collagen is the major 
fibrillar collagen in the meniscus in contrast to articular cartilage, where the major collagen is 
type II. This difference in cell associated matrix protein expression is used as a molecular 
criterion in the distinction of fibrocartilage and hyaline cartilage and thus of meniscus cells 
and chondrocytes. In 1985, the term fibrochondrocytes has been introduced to show the 
typical characteristics of these cells [13].   
Fibrochondrocytes from the inner part of the meniscus are round to oval shaped and 
show a clear cell associated matrix (CAM) with an intense pericellular proteoglycan staining. 
They synthesize large amount of fibrous type I collagen and lower but significant amounts of 
type II collagen and aggrecan. In comparison to this, hyaline chondrocytes produce mainly 
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collagen type II and aggrecan. For this reason they introduced the term “fibrochondrocytes” 
(Figure 1) [14].  
Fibroblast-like cells do not have a cell associated matrix (CAM) and are located in the 
peripheral region of the meniscus. These cells have long cell extensions which are in contact 
with other cells and different parts of the matrix [15].  
A third population of cells in the meniscus is situated in the superficial zone which 
contains cells, known as superficial zone meniscus cells. These cells do not have cell 
extensions. This zone could possibly contain specific progenitor cells with healing potential. 
 
 
 
Recently, we characterized a CD34+ meniscus cell residing in this superficial zone, as 
well as in the vascular zone and in the subsynovial lining. Preliminary data on normal and 
pathological menisci makes us hypothesize that this cell type could be implicated in tissue 
homeostasis and repair/regeneration.  
 
Fig.1. Schematic representation of the human meniscus showing the distinct cell type populations 
and their regional distribution. Fibrochondrocytes are round cells with no cellular projections, located 
in the avascular portion of the meniscus, while fibroblast-like cells are located in the vascular portion 
and reveal thin cytoplasmatic projections. Cells from the superficial area are fusiform.  
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4. In vitro behavior of human meniscus cells 
A recent study assessed survival and proliferation of human meniscus cells in different culture 
conditions and characterized the ECM, produced by these cells [33]. The composition of this 
ECM offers a variable to define the distinct meniscus cell phenotypes.  
Human meniscus cells were isolated enzymatically from visually intact lateral and 
medial menisci. Cells were cultured in monolayer conditions or in alginate gel. The 
composition of the cell associated matrix (CAM) accumulated by the isolated cells during 
culture was investigated and compared to the CAM of articular chondrocytes cultured in 
alginate. For this we used flow cytometry with FITC-conjugated monoclonal antibodies 
against type I collagen, type II collagen and aggrecan. Additional cell membrane marker 
analysis was performed to further identification of different meniscus cell populations in the 
alginate culture conditions and meniscus tissue sections. Proliferation was analyzed using the 
Hoechst 33258 dye method. In some experiments, the effect of TGFβ-1 on some of these 
variables was investigated.    
The CAM of monolayer cultured meniscus cells is composed of high amounts of type 
I and II collagen and low amounts of aggrecan. A major population of alginate cultured 
meniscus cells on the other hand synthesized a CAM containing high amounts of type I 
collagen, low amounts of type II collagen and high amounts of aggrecan. This population is 
CD44+, CD105+, CD34- and CD31-. A minor cell population in the alginate culture did not 
accumulate ECM and was mainly CD34+.  
The proliferation of meniscus cells increased in monolayer culture conditions. The cell 
numbers decreased slightly in the alginate culture, but could increase after the addition of 
TGFβ-1. Articular chondrocytes cultured in alginate synthesized a CAM, composed of low 
amounts of type I collagen and high amounts of type II collagen and aggrecan. The amount of 
type II collagen and aggrecan increased after addition of TGFβ-1 to the culture medium. 
These results demonstrate that the human meniscus is populated by different cell types 
which can be identified by a distinct CAM composition and membrane marker expression. 
Unlike the monolayer culture conditions, the alginate culture conditions appear to favour a 
more fibrochondrocyte-like cell accumulating with a cell associated matrix resembling the 
native tissue composition. This CAM composition is distinctly different from the CAM 
composition of phenotypically stable articular cartilage chondrocytes, cultured in the same 
alginate matrix.  
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5. Rationale for meniscal replacement 
Substantial research has already been performed to substitute the resected meniscus in case of 
a total or partial meniscectomy, in order to (1) prevent or delay cartilage degeneration, (2) to 
improve biomechanics and (3) to diminish pain. The use of different autologous or allogenic 
tissues has been investigated in different surgical approaches. These tissues can be tendon, 
pediculated Hoffa fat pad, periosteal tissue, perichondral tissue, small intestine submucosa or 
meniscal allografts. Meniscus substitution can also be performed by a meniscal scaffold based 
on native polymers (collagen and hyaluronic acid) or purely synthetic scaffolds such as poly-
lactic acid, poly-glucuronic acid or poly-urethane [3,5,16,17,18,19]. Beside meniscal 
allografts and a collagen type I based meniscus scaffold (CMI®, Regen Biologics, Franklin 
Lakes, NJ, USA), none of these materials have been advanced to human clinical use. These 
surgical approaches are based on the concept of a colonization of the acellular scaffold or the 
allograft tissue by host cells in time. These cells are probably derived from the synovium and 
joint capsule (Figure 2).  
 
 
 
The phenotype of these host-derived scaffold-colonizing cells ultimately determines 
the biochemical composition and biomechanical behavior of these repopulated scaffolds or 
Fig. 2. Acellular meniscus grafts or scaffolds (*) are colonized by host cells (arrow) which are 
probably derived from the synovium and the joint capsule (**).  
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tissues. Another critical variable in this approach is the time needed for colonization of the 
scaffold or tissue. Since these scaffolds are biodegradable, the colonization and healing by 
host cells should be faster than the degeneration process (Figure 3). 
Previous animal studies have provided evidence that fresh meniscus allografts are 
quickly invaded by host cells within one month after transplantation [20]. In the human 
model, however, only limited data is available. A previous study has provided evidence that 
this process of colonization is considerably different in the human model. Histological 
sections on specimens taken from transplanted deep-frozen allografts showed a decreased 
cellularity after transplantation, indicating insufficient repopulation of the graft or scaffold 
[21]. 
An increase of the initial cell number in the meniscal substitute can be accomplished 
by (1) transplantation of an in vitro cultured ‘viable’ meniscal allograft or by (2) seeding 
autologous cells, with a proven meniscus repair potential, on or in a biodegradable scaffold 
prior to implantation. 
 
 
 
 
 
 
 
Fig. 3. (A) Ideal degradation kinetic of a resorbable scaffold (grey line) related to tissue healing 
(dashed grey line). The sum of these processes (black line) guarantees the stiffness of the construct. 
(B) In the human model, tissue healing is considered much slower than the resorption of many grafts 
and scaffolds, resulting in reduced stiffness (arrow) and early failure of the construct. 
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6. Possible useful cells for meniscus tissue engineering 
Two different cell options could be used to be seeded on a meniscus implant. We use 
differentiated cells which can synthesize their original ECM and regenerate the tissue [22]. 
Or, we can use progenitor cells which can differentiate in vivo to the desired cell phenotype.  
 
i. Fibrochondrocytes 
Fibrochondrocytes are able to proliferate in a three-dimensional matrix in vitro. In these 
circumstances they express there phenotype with the synthesis of their original ECM. 
Immunohistological staining of this tissue shows fibrocartilagineous tissue [22]. In the clinical 
setting autologous fibrochondrocytes could be harvested by biopsy and isolated. These can be 
taken from the contralateral healthy meniscus or from the torn ipsilateral meniscus which will 
be torn more by this action. Cells could also be isolated from the resected part from the torn 
meniscus but these cells seem to be of minor quality. By consequence the amount of useful 
cells is little. These fibrochondrocytes have already been characterised by flow cytometry. 
Fibrochondrocytes cultivated in alginate produce mainly collagen type I and aggrecan and 
type II collagen in a smaller amount [33]. Fibrochondrocytes, cultivated in monolayer do 
synthesize collagen type I and II but no aggrecan [33]. These results need to be further 
investigated and can be useful for the further research in meniscus tissue engineering. Due to 
the difficulty to harvest a sufficient number of cells, we can conclude that fibrochondrocytes 
may not be the most ideal cells for meniscus tissue engineering.  
 
ii. Articular chondrocytes 
Porcine chondrocytes have been investigated for their use in meniscus tissue engineering. In 
this study, performed by Peretti, autologous chondrocytes have been seeded on allogenic 
meniscus fragments. These meniscus fragments were implanted in the avascular part of the 
meniscus. The investigator described that these chondrocytes were able to synthesize 
meniscal tissue in an in vivo situation [23]. For this reason it is useful to further investigate the 
use of these cells in meniscus tissue engineering strategies.      
 
iii. Fibroblasts 
After implantation of an acellular scaffold or a deep frozen allograft, invasion of these 
scaffolds or grafts by fibroblasts from the synovium, has been observed [24]. In an animal 
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model these cells initially produce a fibrovascular tissue which is transformed into 
fibrocartilagineous tissue [3,25]. Immunofluorescent staining in healthy menisci shows 
CD34+ cells with cell extensions in the peripheral zone of the meniscus. These cells need to 
be further investigated. 
 
iv. Mesenchymal stem cells 
Stem cells have the potential to differentiate into different tissues and have the ability of self 
renewal [22]. Mesenchymal stem cells (MSCs) are able to differentiate into different 
mesenchymal tissues such as bone, cartilage, tendon, fat, neuronal tissue, muscle and bone 
marrow [26,27,28,29]. Bone marrow is one of the most wide spread sources of MSCs used in 
tissue engineering. Besides this, they can also be isolated from other mesenchymal tissues 
such as muscle, fat and synovial membrane [30]. BMSCs can be isolated easily due to their 
potential to adhere in a monolayer culture system. In this situation these cells seem to 
maintain there multipotency  [29].  
MSCs can differentiate into different tissues in an in vitro setting, depending on the 
culture medium and culture conditions. This culture system is based on very dense cell 
cultures, called micropellets. The cells will give rise to cell-cell interactions by forming 
aggregates. If MSCs are cultured as a micropellet in medium supplemented with 
dexamethasone and TGF-β, a (fibro)chondrogenic differentiation will be induced [31,32].  
In an experimental setting, autologous MSCs mixed with hyaluronan have been 
injected in a meniscectomised goat knee. This technique resulted in some cases in the 
neoformation of meniscus. Currently, it is hypothesized that the neoformation could be the 
consequence of the intrinsic regeneration, induced by the extrinsic trophic effect of these cells 
[30]. 
 
v. CD34+ meniscus cells 
Recently, we discovered a possible progenitor cell in the normal human meniscus and the 
subsynovial tissue. These cells, which are CD34+, seem to disappear, from the superficial 
zone, in menisci with a tear or in menisci from osteoarthritic knees [33]. In case of meniscal 
tears, the cells from the superficial zone seem to differentiate into a myofibroblast with alpha 
smooth muscle actin formation [34]. Alpha smooth muscle actin positive cells have been seen 
in torn rotator cuffs, in dermal and tendon scar tissues, and in menisci from the arthritic knee 
[35]. In an animal model, alpha smooth muscle actin positive cells have the capability to 
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migrate into a deep frozen meniscus plug [36]. Our hypothesis is that these CD34+ cells are 
essential for the homeostasis and intrinsic repair of human menisci. Therefore, these cells may 
be of interest for tissue engineering applications.  
 
6. Growth factors 
The differentiation capacity and the production of ECM is determined by an optimal 
environment. Sufficient nutrients, growth factors, cytokines, mechanical stimulation and the 
optimal oxygen concentration are necessary [25]. Growth factors can address certain cells to a 
certain phenotype. Subsequently, we will give a short overview of growth factors with a 
known fibrochondrogenic potential on different cells. 
 Transforming Growth Factor - β1 (TGF-β1) is involved in the development of bone and 
cartilage. In an in vitro cell culture of MSCs, TGF-β1 induces the matrix production (e.g. 
collagen type I, II and aggrecan) and induces chondrogenesis [37].  
 Platelet Derived Growth Factor bb (PDGF bb) influences the chondrogenic potential of 
BMSC [25]. This was investigated by submitting these cells in a medium with TGF-β1 in 
combination with PDGF. These growth factors seem to stimulate the proliferation rate of 
these BMSC’s [38].  PDGF also stimulates the proliferation rate of chondrocytes in a cell 
culture based system of meniscal tissue [39,40].  
 Insuline Growth Factor-I (IGF-I) is the most important anabolic factor for the growth of 
hyaline cartilage. As the inner part of the meniscus resembles articular cartilage rather closely, 
the effect of IGF-I on meniscus tissue has to be investigated in the future [3]. IGF-I induces 
an increased migration if meniscus cells and an increased synthesis of proteoglycans.
 Fibroblast Growth Factor 2 (FGF2) seems to be a strong modulator for stem cell 
proliferation. FGF2 keeps the stromal bone marrow fraction immature. This means that 
osteochondrogenic progenitor cells retain their multipotent character in a cell culture based 
system [41].  
Bone Morphogenetic Protein – 6 (BMP-6) seems to stimulate the chondrogenesis in a 
subpopulation of stromal bone marrow cells [42]. 
 
7. Cells and scaffolds  
For meniscus tissue engineering, cultivated cells need to be seeded on a scaffold. Different 
experiments have been performed. Mueller et al. cultivated meniscal cells, seeded on a CMI, 
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in an in vitro experiment [35]. After three weeks there was a shrinkage of 50% of the collagen 
scaffold. Histological analysis with immunohistology showed the presence of α-smooth 
muscle actin positive cells [35]. In another in vitro experiment the combination of human 
bone marrow derived stem cells with a type I collagen scaffold was investigated. Different 
cell-seeding protocols were performed. This study demonstrated that human bone marrow 
derived MSCs attached and were able to undergo fibrochondrogenic differentiation when 
seeded onto the type I collagen scaffold or injected into it. Injection of the cells resulted in a 
significantly higher number of cells present within the scaffold compared to superficial 
seeding. The clinical application of a cell-scaffold construct injection would result in a higher 
number of cells at the site of injury and thus a decrease in the time needed to completely 
repopulate the scaffold [43].     
 
8. Conclusion 
A functional meniscus is of paramount importance for the homeostasis of the knee joint. In 
case of resection, meniscus substitution by an allograft is a proven concept with satisfactory 
clinical long-term results. Due to specific drawbacks related to the use of allogenic material, 
current research efforts focus on tissue engineering using different cell-sources, scaffolds, 
growth-factors, or a combination thereof. Currently, limited data is available on the 
histological outcome after scaffold implantation. These data show that scaffolds or allografts 
are repopulated by synovium-derived cells and cells derived from the remnant meniscus. The 
number of repopulating cells appears to be limited and their phenotype unknown. Since the 
long-term biochemical and biomechanical characteristics of the graft/scaffold are ultimately 
determined by the cellular phenotype, a combination of a well-characterized cell population 
with a scaffold appears to be a logical option. As it stands now, the applicability of growth-
factors remains very limited in clinical practice. Several candidate cell-types are of interest for 
meniscus tissue engineering. Of these, progenitor cells have the advantage to be easily 
expandable without the loss of their differentiation potential.   
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